1.Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, Li X, Shen G, Peng J, Zheng P, Gu Y, Chen J, Lin M, Deng C, Gao H*, Lu Z*, Zhao Y*, Luo M*. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023 Sep, 621(7980):830-839. (*: corresponding)

2.Li Y, Fang M, Yu H, Wang X, Xue S, Jiang Z, Huang Z, Rong S, Wei X, Lu Z, Luo M*.Nature communication. 2025 May 23;16(1):4783. (*: corresponding)

3.Ding H, Li Y, Fang M, Chen J, Liu L, Lu Z*, Hou J*, and Luo M*. Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease. Journal of Allergy and Clinical Immunology.2023 Jun, 151(6):1622-1633.e10.  (*: corresponding)

4.Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y,  Wilhelm J, Sumer BD, Lea L, Lu Z*, Gao J*, Luo M*. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. Journal For Immunotherapy of Cancer, 2022 May, http://dx.doi.org /10.1136/jitc-2021-003960.(*: corresponding)

5.Gu Y, Cao J, Zhang X, Gao H, Wang Y, Wang J, Jiang X, Zhang J, Shen G, Yang J, Zheng X, Xu J, Lan F, Qu D, Zhao Y, Xu G, Xie Y*, Luo M*, Lu Z* . Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Res, 2022 Jan;32(1):24-37. (*: corresponding)

6.Li S, Luo M, Wang Z, Fu YX, Baran S, Yu H , Gao J. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nature Biomedical Engineering. 2021 May; 5(5):455-466.

7.Yin WM, Li YW, Gu YQ, Luo M*. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacol Sin. 2020 Jul;41(7):902-910. (*: corresponding)

8.Miller J, Luo M, ChenZJ, Gao J, Zhao T. ONM-500 – a novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy. Journal For Immunotherapy of Cancer, 2020 April; 8(A7-A8).

9.Luo M, Liu ZD, Fu Yang-Xin, Gao Jinming. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy, Journal of Controlled Release, 2019, 300：154-160.

10.Luo M., Wang H., Wang Z., Cai H., Lu Z., Huang G., Chen X., Porembka M., Frankel A, Zhijian J. Chen, Gao J. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnoloty. 12(7):648-654, 2017.

11.Luo M, Layla Z. Samandi, Zhaohui Wang, Zhijian J. Chen and Jinming Gao, Synthetic nanovaccines for T cell immunotherapy, Journal of Control Release. 263:200-210, 2017, (Invited review)

12.Wang Z.*, Luo M.*, Mao C., Wei Q., Zhao T., Li Y., Huang G., and Gao J. A Redox Activatable Fluorescent Sensor for the High-Throughput Quantification of Cytosolic Delivery of Macromolecules. Angew. Chem. 2017. 129:1339-1343.

13.Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, Kang X, Luo M, Zou Y, Huang LJ, Amatruda JF, Slone T, Winick N, Scherer PE, Zhang CC. Fasting selectively blocks acute lymphoblastic leukemia development via leptin receptor upregulation. Nature Medicine. 2017. 23(1): 79-90.

14.Zhao T., Huang G., Li Y., Yang S., Ramezani S., Lin Z., Wang Y., Ma X., Zeng Z., Luo M., Boer E., Xie X., Thibodeaux J., Brekken RA, Sun X., Sumer BD, Gao J. A transistor-like pH nanoprobe for tumor detection and image-guided surgery. Nature Biomed. Eng. 2016, DOI: 10.1038/s41551-016-0006.